Depomed Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
DepoMed (DEPO) PT Bumped to $19 at Piper Jaffray, Remains Sidelined
August 4, 2016 7:29 AM EDTPiper Jaffray analyst David Amsellem bumped his price target on DepoMed Inc (NASDAQ: DEPO) to $19.00 (from $18.00) but maintained a Neutral rating.
Amsellem commented, "Depomed reported 2Q16 diluted EPS of $0.27 on revenue of $117M, compared to Street estimates of $0.25 and $118M, respectively. Notably, DEPO... More
Depomed (DEPO) Tops Q2 EPS by 2c
August 3, 2016 4:02 PM EDTDepomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $116.7 million versus the consensus estimate of $118.2 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
... More